Drugs / Direct Oral Anticoagulant (DOAC)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05498428 Background | Nov 2022 → Aug 2027 expected | non-small cell lung carcinoma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Direct Oral Anticoagulant (DOAC) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05498428 ↗ |
| Route | Oral | “DOAC will be administered orally.” NCT05498428 ↗ |